Braveheart Bio, Inc. (BRVE) vs Hemab Therapeutics Holdings, Inc. (COAG)

Braveheart Bio, Inc. and Hemab Therapeutics Holdings, Inc. are both Biotechnology companies. Braveheart Bio, Inc. and Hemab Therapeutics Holdings, Inc. are of similar size ($1.8B and $1.8B). Across the 6 metrics below, Hemab Therapeutics Holdings, Inc. leads on 4 and Braveheart Bio, Inc. on 2.

Valuation

Metric BRVE COAG Biotechnology median
P/E n/m n/m 11.36
P/S n/m n/m 9.12
P/B 2.05 4.47 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales n/m n/m 8.56
Earnings yield (61.95%) (105.55%) (34.18%)
Free cash flow yield (4.69%) (4.64%) (23.62%)

Profitability

Metric BRVE COAG Biotechnology median
Gross margin — — 67.24%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (50.28%)
Return on assets 0.00% 0.00% (45.89%)
Return on invested capital (28.66%) 0.00% 0.00%

Growth

Metric BRVE COAG Biotechnology median
Revenue growth (TTM) — — 6.96%
EPS growth (last fiscal year) — — 29.86%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric BRVE COAG Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.57 33.86 4.72
Net debt to EBITDA 1.34 — 1.01

Dividend

Metric BRVE COAG Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric BRVE COAG Biotechnology median
Market cap 1.84b 1.84b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack